EU urologists say case is clear for more prostate screening
This article was originally published in Clinica
Executive Summary
Three-quarters of the 346,000 or so new cases of prostate cancer in Europe every year are diagnosed in the early stages of disease, resulting in an 80% survival rate, thanks to screening initiatives. So said the European Association of Urology (EUA) last week, in calls to improve prostate screening (for benign prostatic hyperplasia and cancer) and care for the other leading urological conditions: incontinence and erectile dysfunction.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.